4.6 Article

Peripheral Tissue Homing Receptors Enable T Cell Entry into Lymph Nodes and Affect the Anatomical Distribution of Memory Cells

期刊

JOURNAL OF IMMUNOLOGY
卷 191, 期 5, 页码 2412-2425

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1300651

关键词

-

资金

  1. Public Health Service [CA78400, AI068836, AI007496, HL007284, GM007267]
  2. Robert R. Wagner Fellowship
  3. University of Virginia Cancer Center

向作者/读者索取更多资源

Peripheral tissue homing receptors enable T cells to access inflamed nonlymphoid tissues. In this study, we show that two such molecules, E-selectin ligand and alpha(4)beta(1) integrin, enable activated and memory T cells to enter lymph nodes (LN) as well. This affects the quantitative and qualitative distribution of these cells among regional LN beds. CD8 memory T cells in LN that express these molecules were mostly CD62L(lo) and would normally be classified as effector memory cells. However, similar to central memory cells, they expanded upon Ag re-encounter. This led to differences in the magnitude of the recall response that depended on the route of immunization. These novel cells share properties of both central and effector memory cells and reside in LN based on previously undescribed mechanisms of entry.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

Victor H. Engelhard, Rebecca C. Obeng, Kara L. Cummings, Gina R. Petroni, Angela L. Ambakhutwala, Kimberly A. Chianese-Bullock, Kelly T. Smith, Amanda Lulu, Nikole Varhegyi, Mark E. Smolkin, Paisley Myers, Keira E. Mahoney, Jeffrey Shabanowitz, Nico Buettner, Emily H. Hall, Kathleen Haden, Mark Cobbold, Donald F. Hunt, Geoffrey Weiss, Elizabeth Gaughan, Craig L. Slingluff

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Pharmacology & Pharmacy

COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia

Garth W. Strohbehn, Brian L. Heiss, Sherin J. Rouhani, Jonathan A. Trujillo, Jovian Yu, Alec J. Kacew, Emily F. Higgs, Jeffrey C. Bloodworth, Alexandra Cabanov, Rachel C. Wright, Adriana K. Koziol, Alexandra Weiss, Keith Danahey, Theodore G. Karrison, Cuoghi C. Edens, Iazsmin Bauer Ventura, Natasha N. Pettit, Bhakti K. Patel, Jennifer Pisano, Mary E. Strek, Thomas F. Gajewski, Mark J. Ratain, Pankti D. Reid

Summary: In this single-arm phase II trial, low-dose tocilizumab was associated with rapid improvement in fever and CRP levels in hospitalized COVID-19 patients. There was no significant relationship between dose and fever resolution or CRP decline over the dose range of 40-200 mg. For recovered patients, the median time to clinical recovery was 3 days. This study provides rationale for further randomized, controlled trials of low-dose tocilizumab in COVID-19.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Article Oncology

Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy

Nicole K. Yun, Sherin J. Rouhani, Christine M. Bestvina, Ethan M. Ritz, Brendan A. Gilmore, Imad Tarhoni, Jeffrey A. Borgia, Marta Batus, Philip D. Bonomi, Mary Jo Fidler

Summary: This study investigated the predictive value of NLR and other markers in patients with EGFR-mutated NSCLC undergoing TKI therapy. The results showed that high NLR values were associated with worse survival outcomes, suggesting its potential as a predictive biomarker for treatment intensification. Prospective validation of NLR is warranted.

CANCERS (2021)

Article Multidisciplinary Sciences

Sensitive detection and quantification of SARS-CoV-2 in saliva

Mustafa Fatih Abasiyanik, Blake Flood, Jing Lin, Sefika Ozcan, Sherin J. Rouhani, Athalia Pyzer, Jonathan Trujillo, Chaojie Zhen, Ping Wu, Stephen Jumic, Andrew Wang, Thomas F. Gajewski, Peng Wang, Madeline Hartley, Bekim Ameti, Rachael Niemiec, Marian Fernando, Vasudha Mishra, Peter Savage, Bulent Aydogan, Cindy Bethel, Scott Matushek, Kathleen G. Beavis, Nishant Agrawal, Jeremy Segal, Savas Tay, Evgeny Izumchenko

Summary: Saliva has significant advantages as a test medium for detecting SARS-CoV-2 infection, with a developed testing pipeline showing high effectiveness in detecting infected cases in both outpatient and inpatient settings. The saliva-based testing has the potential for higher sensitivity in detecting low-abundance viral loads, making it a reliable alternative to traditional testing methods.

SCIENTIFIC REPORTS (2021)

Article Oncology

Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients

Amanda M. Lulu, Kara L. Cummings, Erin D. Jeffery, Paisley T. Myers, Dennis Underwood, Rachel M. Lacy, Kimberly A. Chianese-Bullock, Craig L. Slingluff, Susan C. Modesitt, Victor H. Engelhard

Summary: A study found preexisting immune memory to cancer-expressed phosphopeptides in most healthy donors, indicating exposure to common microbial agents, but with significant variability. The research suggests that the immunogens generating phosphopeptide-specific immune memory are rare infectious agents or early cancer cells with distinct phosphoproteome dysregulations, and repetitive immunogenic exposures occur in individual donors. Overall, enhancing phosphopeptide-specific T-cell responses could be a useful approach to improve tumor immunotherapy.

CANCER IMMUNOLOGY RESEARCH (2021)

Article Oncology

Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma

Kevin T. Lynch, Samuel J. Young, Max O. Meneveau, Nolan A. Wages, Victor H. Engelhard, Craig L. Slingluff, Ileana S. Mauldin

Summary: The presence of TLS in cutaneous melanoma metastases is associated with increased intratumoral lymphocyte infiltration and improved overall survival in patients. Different types of TLS have varying effects on patient survival, indicating potential regulatory or antigen-driven immune responses.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Multidisciplinary Sciences

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

Stanley Gutiontov, William Tyler Turchan, Liam F. Spurr, Sherin J. Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell, Steven J. Chmura, Aditya Juloori, Philip C. Hoffman, Mark K. Ferguson, Jessica S. Donington, Jyoti D. Patel, Everett E. Vokes, Ralph R. Weichselbaum, Christine M. Bestvina, Jeremy P. Segal, Sean P. Pitroda

Summary: The study found that the loss of CDKN2A function is associated with poorer clinical outcomes in advanced NSCLC patients treated with ICB, even in high PD-L1 and high TMB tumors. This novel finding should be further validated and may serve as a potential therapeutic target.

SCIENTIFIC REPORTS (2021)

Article Oncology

Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies

Sherin Juliet Rouhani, Jovian Yu, Daniel Olson, Yuanyuan Zha, Apameh Pezeshk, Alexandra Cabanov, Athalia R. Pyzer, Jonathan Trujillo, Benjamin A. Derman, Peter O'Donnell, Andrzej Jakubowiak, Hedy L. Kindler, Christine Bestvina, Thomas F. Gajewski

Summary: The immunogenicity and side effect profiles of COVID-19 vaccines in cancer patients are not well understood. Patients with solid tumors develop similar antibody and T cell responses to the vaccines compared to healthy individuals. However, patients on B-cell directed therapies may have decreased antibody titers, while many seronegative patients still develop a T cell response. The study also highlights the need for adrenal insufficiency patients to take stress dose steroids during vaccination.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines

Robin Reschke, Jason W. Shapiro, Jovian Yu, Sherin J. Rouhani, Daniel J. Olson, Yuanyuan Zha, Thomas F. Gajewski

Summary: Immune checkpoint blockade is a successful therapeutic approach for many types of cancer, but it often leads to immune-related adverse events (irAE) that can be life-threatening. In this study, researchers analyzed tissues from patients with irAE dermatitis using various techniques and found important insights into the immunologic mechanisms and functional phenotypes associated with irAE.

CANCER IMMUNOLOGY RESEARCH (2022)

Article Multidisciplinary Sciences

Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity

Priscilla S. Briquez, Sherin J. Rouhani, Jovian Yu, Athalia R. Pyzer, Jonathan Trujillo, Haley L. Dugan, Christopher T. Stamper, Siriruk Changrob, Anne Sperling, Patrick C. Wilson, Thomas F. Gajewski, Jeffrey A. Hubbell, Melody A. Swartz

Summary: Patients with COVID-19 may develop autoantibodies against AngII, which correlates with blood pressure dysregulation, lower blood oxygenation, and increased disease severity. The presence of these autoantibodies suggests potential epitope mimicry between AngII and SARS-CoV-2 proteins.

SCIENCE ADVANCES (2022)

Article Oncology

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events

Kristen Mathias, Sherin Rouhani, Daniel Olson, Anne R. Bass, Thomas F. Gajewski, Pankti Reid

Summary: This article examines the clinical utility of rheumatic autoantibodies (rhAbs) in diagnosing immune-related adverse events (irAEs). The study finds a significant association between rhAbs and rheumatic irAEs, and shows that irAEs are linked to better overall survival.

ONCOLOGIST (2023)

Meeting Abstract Oncology

The prognostic value of neutrophil-to-lymphocyte ratio in patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer (NSCLC).

Nicole Yun, Sherin Juliet Rouhani, Brendan Gilmore, Ethan M. Ritz, Christine M. Bestvina, Imad Tarhoni, Marta Batus, Jeffrey Allen Borgia, Philip D. Bonomi, Mary J. Fidler

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Oncology

COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis.

Garth W. Strohbehn, Brian L. Heiss, Sherin J. Rouhani, Jonathan A. Trujillo, Athalia R. Pyzer, Jovian Yu, Alec J. Kacew, Alexandra Weiss, Spring Maleckar, Rachel Wright, Adriana Koziol, Bethany Martell, Keith Danahey, Theodore G. Karrison, Cuoghi Edens, Iazsmin Bauer Ventura, Natasha Pettit, Bakhti Patel, Jennifer Pisano, Mary Strek, Thomas F. Gajewski, Mark J. Ratain, Pankti D. Reid

CLINICAL CANCER RESEARCH (2020)

Meeting Abstract Oncology

Tissue banking from patients with SARS-CoV-2 (COVID-19) infection.

Emily F. Higgs, Blake A. Flood, Athalia R. Pyzer, Sherin J. Rouhani, Jonathan A. Trujillo, Kyle R. Cron, Alexandra Cabanov, Jessica Fessler, Jeffrey Bloodworth, Kathleen Beavis, Kiang-Teck J. Yeo, Randy F. Sweis, Yuanyuan Zha, Thomas F. Gajewski

CLINICAL CANCER RESEARCH (2020)

Meeting Abstract Oncology

Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection.

Alexandra Cabanov, Blake A. Flood, Jeffrey Bloodworth, Emily F. Higgs, Jessica Fessler, Michael Y. K. Leung, Kyle R. Cron, Jonathan Trujillo, Athalia R. Pyzer, Sherin Rouhani, Garth Strohbehn, Brian Heiss, Mark Ratain, Pankti Reid, Kiang-Teck J. Yeo, Randy F. Sweis, Yuanyuan Zha, Thomas F. Gajewski

CLINICAL CANCER RESEARCH (2020)

暂无数据